Physician profile
Athanasios Verras
NPI 1508824392
$1,309.45
in general payments reported to CMS, 2019-2025
13 companies · $250 in 2025
The $250 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.71 · 2020: $96.19 · 2021: $204 · 2022: $310 · 2023: $238 · 2024: $121 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $235.59 | 2020-2025 | |
| Baxter Healthcare | $217.08 | 2022 | |
| Glaxosmithkline, LLC. | $187.22 | 2020-2025 | Bexsero, Rotarix, Boostrix |
| Sanofi Pasteur INC. | $177.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $128.82 | 2020-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Cranial Technologies, INC | $111.94 | 2019-2025 | Doc Band |
| Seqirus USA INC | $51.72 | 2024-2025 | Flucelvax |
| Welch Allyn | $43.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.53 | 2019 | |
| Emmaus Medical, INC. | $35.50 | 2021-2022 | |
| Phadia US INC. | $34.50 | 2022-2023 | Immunocap |
| Genentech USA, INC. | $34.46 | 2020 | |
| Alk-Abello, INC | $15.24 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Athanasios Verras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.